Page last updated: 2024-08-23

acetylgalactosamine and Nausea

acetylgalactosamine has been researched along with Nausea in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Anderson, KE; Balwani, M; Bissell, DM; Bonkovsky, HL; Chen, J; Garg, P; Gouya, L; Harper, P; Horie, Y; Ivanova, A; Kauppinen, R; Keel, SB; Kim, JB; Ko, JJ; Langendonk, JG; Liu, S; Minder, E; Parker, C; Peiró, PA; Penz, C; Phillips, J; Rees, DC; Sardh, E; Silver, SM; Simon, AR; Stein, PE; Stölzel, U; Sweetser, MT; Vaishnaw, A; Vassiliou, D; Ventura, P; Wang, B; Wang, JD; Windyga, J	1

Trials

1 trial(s) available for acetylgalactosamine and Nausea

Article	Year
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. The New England journal of medicine, 2020, 06-11, Volume: 382, Issue:24 Topics: Acetylgalactosamine; Adult; Aminolevulinic Acid; Double-Blind Method; Fatigue; Female; Humans; Injections, Subcutaneous; Least-Squares Analysis; Liver; Male; Nausea; Pain; Patient Outcome Assessment; Porphobilinogen; Porphyria, Acute Intermittent; Pyrrolidines; Renal Insufficiency, Chronic; RNAi Therapeutics; Transaminases	2020

Article

Year

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.

The New England journal of medicine, 2020, 06-11, Volume: 382, Issue:24

Topics: Acetylgalactosamine; Adult; Aminolevulinic Acid; Double-Blind Method; Fatigue; Female; Humans; Injections, Subcutaneous; Least-Squares Analysis; Liver; Male; Nausea; Pain; Patient Outcome Assessment; Porphobilinogen; Porphyria, Acute Intermittent; Pyrrolidines; Renal Insufficiency, Chronic; RNAi Therapeutics; Transaminases

2020